B22EES1-8-3 Compound for Inflammation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune diseases, such as rheumatoid arthritis and sepsis, often rely on expensive immunotherapeutics like TNF-α inhibitors, which have adverse effects, and there is a need for more effective and safer alternatives that can modulate immune responses and reduce inflammation without severe side effects.
Innovation Solution
Development of a substantially pure anti-inflammatory compound, B22EES1-8-3, isolated from Cimicifuga racemosa and its counterparts, which inhibits LPS-induced TNF-α production, thereby reducing inflammation and immune response activation, and is used in pharmaceutical compositions to treat various inflammatory and immune-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If TNF-α inhibitors are used to treat inflammatory diseases, then inflammation is suppressed, but adverse effects occur
Solution Approach 1:
The patent extracts and isolates a specific active compound (B22EES1-8-3) from the crude extract of Cimicifuga racemosa. This extraction process separates the therapeutic anti-inflammatory component from other plant constituents that may cause adverse effects, thereby maintaining inflammation suppression while reducing side effects.
Solution Approach 2:
The patent changes the chemical parameter by isolating a specific compound with defined chemical structure and purity (≥95%) from the crude plant extract. This parameter change from crude extract to purified compound alters the safety profile while preserving the anti-inflammatory activity against LPS-induced TNF-α production.
2Reliability
If expensive immunotherapeutics are used, then treatment effectiveness is improved, but cost increases
Solution Approach 1:
The patent replaces expensive immunotherapeutics with a cost-effective natural product derivative. The compound B22EES1-8-3 can be produced through plant cultivation and extraction processes that are significantly cheaper than synthetic immunosuppressants or biologic agents, making treatment more accessible while maintaining effectiveness in suppressing TNF-α production.
Solution Approach 2:
The patent identifies and isolates a naturally occurring compound that copies the therapeutic effect of expensive immunotherapeutics (suppressing TNF-α production) but achieves this through a simpler, more economical natural product pathway rather than complex synthetic or biologic manufacturing.
3Object-affected harmful factors
If current anti-inflammatory treatments are used, then inflammation is reduced, but safety is compromised
Solution Approach 1:
The patent extracts the specific active compound B22EES1-8-3 from Cimicifuga racemosa, separating it from other plant components. This extraction ensures that the anti-inflammatory effect is achieved through a well-defined compound with reduced risk of unpredictable side effects from crude plant material or interactions with other constituents.
Solution Approach 2:
The patent changes the purity parameter from crude extract to highly purified compound (≥95% purity). This parameter change enhances safety by eliminating contaminants and undefined components while maintaining the therapeutic effect of suppressing LPS-induced TNF-α production in macrophages.
Data Source
AI summary
The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.